The global market for biosimilars will be worth nearly $2.5 billion this year, according to a new study by British market research firm Visiongain. They forecast the $2.445 billion market size marked more than 20% of growth from 2012 and would account for about 2% of the overall market for biologics. The market is expected to grow rapidly through 2023 as biosimilars hit the market in the United States and European Union. Read the full story